Warmuth M - Search Results

1

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M. Danhauser-Riedl S, et al. Among authors: warmuth m. Cancer Res. 1996 Aug 1;56(15):3589-96. Cancer Res. 1996. PMID: 8758931

2

Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.

Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ, Druker B, Griffin JD, Emmerich B, Ullrich A. Hallek M, et al. Among authors: warmuth m. Br J Haematol. 1996 Jul;94(1):5-16. doi: 10.1046/j.1365-2141.1996.6102053.x. Br J Haematol. 1996. PMID: 8757502

3

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.

Warmuth M, Bergmann M, Priess A, Häuslmann K, Emmerich B, Hallek M. Warmuth M, et al. J Biol Chem. 1997 Dec 26;272(52):33260-70. doi: 10.1074/jbc.272.52.33260. J Biol Chem. 1997. PMID: 9407116 Free article.

4

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

Warmuth M, Danhauser-Riedl S, Hallek M. Warmuth M, et al. Ann Hematol. 1999 Feb;78(2):49-64. doi: 10.1007/s002770050473. Ann Hematol. 1999. PMID: 10089019 Review.

5

Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Schaeffer M, Schneiderbauer M, Weidler S, Tavares R, Warmuth M, de Vos G, Hallek M. Schaeffer M, et al. Among authors: warmuth m. Mol Cell Biol. 2001 Dec;21(23):8068-81. doi: 10.1128/MCB.21.23.8068-8081.2001. Mol Cell Biol. 2001. PMID: 11689697 Free PMC article.

6

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains.

Stanglmaier M, Warmuth M, Kleinlein I, Reis S, Hallek M. Stanglmaier M, et al. Among authors: warmuth m. Leukemia. 2003 Feb;17(2):283-9. doi: 10.1038/sj.leu.2402778. Leukemia. 2003. PMID: 12592324

7

The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.

Schuster C, Forster K, Dierks H, Elsasser A, Behre G, Simon N, Danhauser-Riedl S, Hallek M, Warmuth M. Schuster C, et al. Among authors: warmuth m. Blood. 2003 Jan 15;101(2):655-63. doi: 10.1182/blood-2002-01-0043. Epub 2002 Sep 12. Blood. 2003. PMID: 12393654 Free article.

8

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M. Warmuth M, et al. Blood. 2003 Jan 15;101(2):664-72. doi: 10.1182/blood-2002-01-0288. Epub 2002 Sep 5. Blood. 2003. PMID: 12393636 Free article.

9

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.

Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S. Hu Y, et al. Among authors: warmuth m. Nat Genet. 2004 May;36(5):453-61. doi: 10.1038/ng1343. Epub 2004 Apr 18. Nat Genet. 2004. PMID: 15098032 Free article.

10

Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner.

Mitina O, Warmuth M, Krause G, Hallek M, Obermeier A. Mitina O, et al. Among authors: warmuth m. Ann Hematol. 2007 Nov;86(11):777-85. doi: 10.1007/s00277-007-0344-0. Epub 2007 Aug 1. Ann Hematol. 2007. PMID: 17668209

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters